Corneal Transplant — Cost, Top Hospitals & Success Rates | MyMedicPlus

Corneal transplantation (keratoplasty) is the replacement of a diseased or damaged cornea with healthy donor corneal tissue, restoring corneal clarity and visual function. The cornea is the transparent dome-shaped front surface of the eye responsible for approximately 65–75% of the eye's refracting power; its transparency depends on precise arrangement of stromal collagen fibrils and active endothelial cell pump function. Corneal transplantation is the most frequently performed tissue transplantation procedure globally — approximately 185,000 corneal transplants are performed annually worldwide — and the most successful solid tissue transplant, with 1-year graft survival exceeding 90% in low-risk cases. The cornea is an immunologically privileged tissue (lacking blood vessels and lymphatics), which substantially reduces rejection risk compared to other organ transplants — though immune-mediated rejection remains the most common cause of graft failure (occurring in 10–15% of cases). Modern corneal surgery has evolved from full-thickness penetrating keratoplasty (PK) — the historical standard — to tissue-selective lamellar keratoplasty techniques: DSAEK (Descemet's Stripping Automated Endothelial Keratoplasty) and DMEK (Descemet's Membrane Endothelial Keratoplasty) for endothelial disease, and DALK (Deep Anterior Lamellar Keratoplasty) for stromal disease with intact endothelium. These modern lamellar techniques preserve recipient tissue, have lower rejection rates (DMEK rejection rate <1% vs. 15–20% for PK), achieve superior visual outcomes, and avoid the structural vulnerability of full-thickness grafts.

Corneal transplant is indicated for corneal disease causing visually significant opacity, edema, or irregularity not correctable by other means. Keratoconus (progressive corneal thinning and protrusion): the most common indication for corneal transplant in developed countries (35–40%); managed initially with RGP contact lenses, then corneal crosslinking (CXL) to halt progression; when contact lens intolerance or visual acuity is insufficient, DALK (preserving recipient endothelium) is preferred — avoids endothelial rejection risk; visual outcomes excellent with DALK (BCVA 6/12 or better in 85–90%). Bullous keratopathy (corneal edema from endothelial decompensation): pseudophakic bullous keratopathy (following cataract surgery with endothelial damage) and Fuchs' endothelial dystrophy (hereditary progressive endothelial cell loss) — treated with DMEK or DSAEK (endothelial transplant only; stroma and epithelium preserved). DMEK achieves the fastest visual recovery (6/12 in 50% at 1 month, 6/9 in 80% at 1 year) with the lowest rejection rate (<1%). Corneal scars from: trachoma (leading cause of infectious blindness globally), herpes simplex keratitis (recurrent viral scarring — most common infectious cause of corneal blindness in the developed world), bacterial and fungal keratitis, chemical burns, trauma. Corneal dystrophies: macular, stromal, lattice, granular corneal dystrophies causing visual impairment — PK or DALK depending on layers involved. Corneal degeneration from advanced bullous keratopathy unresponsive to medical management: PK.

Corneal transplant candidacy requires: visually significant corneal pathology not correctable by spectacles or contact lenses; potential for visual improvement (adequate macular and optic nerve function — assessed by visual potential testing, retinal examination, and electrophysiology if needed); quiet ocular surface (active infection, severe blepharitis, or dry eye must be optimized before surgery); adequate ocular surface anatomy for transplant; absence of absolute contraindications (irreversibly damaged retina or optic nerve with no visual potential). Pre-operative evaluation: corneal topography/tomography (Scheimpflug imaging — Pentacam, Orbscan) for keratoconus staging and surgical planning; anterior segment OCT (AS-OCT) for lamellar surgery planning and Descemet's membrane visualization; specular microscopy of fellow eye for comparative endothelial cell count; IOP assessment; fundus evaluation; systemic health for anesthesia. Donor tissue requirements: eye banks provide ethically sourced, serologically tested (HIV, hepatitis B/C, syphilis negative) donor corneas with adequate endothelial cell counts (>2,000 cells/mm² for endothelial transplants; >1,800 for DALK/PK) and appropriate age (typically 2–75 years). Tissue matching is not performed for standard corneas (unlike kidney/heart transplant) as HLA matching is not routinely done and does not significantly improve outcomes in primary transplants. However, HLA matching is considered for high-risk re-grafts with multiple prior rejections. Tissue availability varies dramatically by country — India has established a national eye bank network (Eye Bank Association of India) but significant regional shortages remain.

Treatment options are tailored to individual patient needs based on disease severity, comorbidities, patient preference, and clinical guidelines. The treating physician will discuss all available options and recommend an approach based on the complete clinical assessment.

First-line treatment follows established evidence-based protocols with well-documented efficacy and safety profiles. This may involve pharmacological therapy with single or combination agents, procedural intervention using minimally invasive or open techniques, or a combination approach integrating multiple treatment modalities.

Second-line options are considered when primary treatment fails to achieve therapeutic targets or is not tolerated. These include alternative agents within the same drug class, different treatment modalities, or escalation to more intensive therapy at specialist centres.

Emerging treatments available through clinical trials or specialist referral include novel targeted agents, biological therapies, advanced procedural techniques, and gene therapy approaches for selected conditions. Patients are encouraged to discuss eligibility for clinical trials with their specialist. Treatment intensity is regularly reassessed and adjusted based on clinical response, ensuring optimal outcomes while minimising unnecessary exposure to treatment-related risks.

The selection of treatment approach follows a systematic assessment of clinical factors, patient preferences, and risk-benefit considerations. Evidence-based guidelines from professional societies including WHO, NICE, and relevant specialty organisations inform treatment selection and protocol design.

Combination treatment strategies are increasingly favoured where multiple modalities provide synergistic benefit. The sequence and intensity of treatment components are titrated based on patient response at defined assessment intervals. Patients not responding adequately to initial treatment undergo structured reassessment to identify alternative approaches or combination strategies.

Personalised medicine approaches using biomarker profiling and genetic analysis are emerging as tools to predict treatment response and guide individualised treatment selection in eligible patients. Multidisciplinary team review ensures all relevant clinical expertise informs treatment decisions for complex cases.

Corneal transplantation achieves remarkable visual outcomes when performed for appropriate indications. DMEK for Fuchs' endothelial dystrophy: BCVA 6/12 or better in 85–90% at 1 year; BCVA 6/6 in 35–50% (superior to PK); rejection rate <1% (dramatically lower than PK rejection rate of 15–20%); faster visual recovery (functional vision in 1–3 months vs. 6–12 months for PK). DSAEK for bullous keratopathy: BCVA 6/12 in 80–85% at 1 year; rejection rate 5–8%; easier surgical technique than DMEK (wider adoption). DALK for keratoconus: BCVA 6/12 in 90% at 1 year; no endothelial rejection (only stromal rejection possible, very rare); structural integrity better than PK (no full-thickness wound); contact lenses can still be used if some irregular astigmatism remains. PK (penetrating keratoplasty): 1-year graft survival 90% in primary, low-risk cases; 5-year survival 75–80%; 10-year survival 60–70%. Visual outcomes for PK take longer to fully develop (12–18 months as wound healing and suture removal allow refraction to stabilize). Spectacle or contact lens correction is usually still required post-PK due to irregular post-operative astigmatism. Corneal transplant from trachoma blindness (most common cause of global infectious blindness): restores functional vision in 70–80% and economic productivity in rural communities — outstanding public health impact.

Corneal graft rejection: the most common cause of late graft failure — occurs in 10–15% of primary PK (higher risk with vascularized corneas, anterior chamber abnormalities, keratoconus with neovascularization, repeat grafts). Rejection presents as reduced vision, pain, redness, and the hallmark 'rejection line' or Khodadoust line (linear endothelial rejection). Treatment: intensive topical corticosteroids (prednisolone 1% every 1–2 hours) and sometimes systemic steroids — reversal in 80% if caught early. Prevention: long-term topical steroids (minimum 1 year) plus patient education to seek help immediately for any symptoms. Primary graft failure: graft fails to clear due to damaged endothelium in the donor tissue — rare (<1%) with modern eye bank quality control; requires re-grafting. Infectious keratitis: bacterial or fungal infection in the graft — risk increased by immunosuppressive topical steroids; requires intensive topical antibiotics/antifungals. Suture-related complications in PK: suture loosening causing astigmatism, suture abscess, suture-associated vascularization — managed by suture removal or replacement. DMEK-specific complications: graft detachment (the most common — 30–40% require rebubbling — air injection into anterior chamber to reattach the graft; >90% successfully reattach with rebubbling); primary graft failure if tissue damaged during preparation; technical difficulty in high surgeons' learning curve (first 25 cases). Elevated IOP and glaucoma after PK in 10–30% (from surgery, steroid-induced, or angle damage). Cataract progression post-PK from steroid use in phakic patients.

Structured follow-up is essential to optimise treatment outcomes and ensure early identification of complications or disease recurrence. The follow-up schedule is individuialised based on treatment type, disease characteristics, and patient-specific factors.

Standard follow-up scheduling involves: early post-treatment review at 2-4 weeks to assess initial response and manage any early side effects; monthly assessments for the first 3 months to monitor treatment response and titrate therapy as needed; quarterly review for the remainder of the first year; and annual long-term follow-up for stable patients.

Each follow-up visit includes clinical examination, relevant laboratory testing as indicated by the treatment protocol, imaging studies at defined intervals based on condition-specific guidelines, and assessment of patient-reported outcomes and quality of life.

Patients are provided with clear guidance on symptoms requiring urgent medical review between scheduled appointments, including signs of serious complications or disease progression. Remote consultation options including telephone and video review facilitate access to specialist advice between face-to-face appointments. Long-term surveillance continues indefinitely for chronic conditions, with frequency adjusted based on individual risk profile and clinical response.

Corneal transplantation costs include the donor tissue, surgical procedure, and post-operative monitoring. In the USA, PK or DMEK: $15,000–$30,000 per eye including surgery, eye bank tissue ($2,000–$4,000), hospitalization, and follow-up; immunosuppressive drops $100–$300/month ongoing. UK NHS: free for eligible patients; private £8,000–£15,000. In India, corneal transplant at leading ophthalmic centers (Sankara Nethralaya Chennai, LV Prasad Hyderabad, Aravind Eye Hospitals, Shroff Eye Centre Delhi, Narayana Nethralaya Bangalore): PK/DSAEK: ₹50,000–₹1,50,000 ($600–$1,800) including donated tissue (at government eye banks, tissue is supplied free; private eye banks charge ₹20,000–₹50,000 for tissue); DMEK: ₹80,000–₹2,00,000 ($960–$2,400). Post-operative steroid drops: ₹300–₹800/month ($3.60–$9.60) in India versus $100–$300/month in USA. Tissue availability in India: India has a severe corneal tissue shortage (80,000+ eyes needed annually vs. ~30,000 recovered) — wait times exist. International donors are not available; medical tourists must understand that donor tissue may cause scheduling uncertainty. Thailand: corneal transplant $5,000–$12,000; Turkey: $4,000–$10,000; Singapore: $8,000–$20,000. India's specialized eye care hospitals like Sankara Nethralaya and LV Prasad Eye Institute have internationally recognized corneal disease programs with fellowship-trained corneal surgeons achieving outcomes comparable to best international centers.

Alternative treatment approaches are considered when first-line treatment is contraindicated, not tolerated, or fails to achieve therapeutic targets. The range of alternatives depends on the specific condition and patient circumstances.

Conservative management with watchful waiting and close monitoring is appropriate for mild or asymptomatic presentations where the natural history is favourable and intervention risks outweigh expected benefits. Regular surveillance allows timely escalation when clinical criteria for active treatment are met.

Non-pharmacological approaches including physiotherapy, occupational therapy, dietary optimisation, and structured lifestyle modification programmes form the foundation of management for many conditions. These interventions reduce symptom burden, improve functional capacity, and may delay or eliminate the need for pharmacological or procedural treatment.

Alternative pharmacological approaches include agents from different drug classes with different mechanisms of action, dosing strategies, or delivery routes. Clinical trials evaluating novel agents may offer access to emerging therapies not yet in routine clinical practice.

Surgical alternatives range from minimally invasive endoscopic or laparoscopic approaches to open surgery, each appropriate for different clinical scenarios. Complementary and integrative medicine approaches including acupuncture, herbal medicine, and mind-body therapies may provide symptomatic benefit for some patients as adjuncts to conventional care, though evidence quality varies and potential interactions with conventional treatment should be discussed with a qualified practitioner.